Immuneering To Present Atebimetinib ctDNA Data Showing Durable Tumor Shrinkage At AACR 2026

Immuneering Corporation (NASDAQ: IMRX) announced it will present data on atebimetinib at the AACR Annual Meeting from April 17-22, 2026, in San Diego, CA. The presentation will focus on the drug's ability to achieve durable tumor shrinkage in patients with RAS-mutant solid tumors, showing that acquired MAPK pathway alterations are rarely observed in treated patients. This suggests that atebimetinib may provide a more sustained clinical benefit compared to conventional MAPK inhibitors.